International Society for Stem Cell Application (ISSCA) Presents Certification Program in Natural Killers and CAR-T Cells
The International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group (GSCG), is excited to introduce its groundbreaking inaugural certification program in Natural Killers (NK) and CAR-T (Chimeric Antigen Receptor Tcell) Cells. This two-day hands-on training program, led by Dr.Hassan Bennani, an expert in the application of NK and CAR-T Cells, is designed to equip physicians with advanced skills in anti-aging, immune system support, and advanced cancer therapy. The first-ever course offering by ISSCA will take place on May 12th and 13th in Jakarta, Indonesia.
Importance of NK and CAR-T Cell Therapies
NK cells, the vital type of white blood cells, play a significant role in the innate immune system. Autologous Enriched NK cell therapy has demonstrated the potential to directly attack and destroy abnormal cells. Mesenchymal Stem Cells (MSCs) are another crucial stem cell type that maintain cell balance, replace damaged or dying cells, and can potentially regenerate damaged tissue under pathological conditions. CAR-T cell therapy is a groundbreaking immunotherapy that uses the patient’s own Tcells to recognize and eliminate certain cancers.
Program Content and Structure
The certification program offered by ISSCA gives physicians comprehensive guidance and hands-on practice in collecting tissue samples, using laboratory equipment, processing and isolating various cellular products, and administering treatment to patients. The program encompasses cell culture basics, quality control tests, stem cell processing and regulations in a certified facility, implementation of regulatory and clinical guidelines, clinical procedures, and case protocols for different indications.
Benefits of the ISSCA Certification Program
The ISSCA Certification Program in Natural Killers and CAR-T Cells is expected to offer a wide array of benefits to participating physicians, ultimately enabling them to provide exceptional care to their patients. The advantages of this groundbreaking certification program include:
Access to cutting-edge therapies: The program focuses on NK and CAR-T cell therapies, which have demonstrated significant potential in anti-aging, immune system support, and advanced cancer therapy. Physicians participating in this program will learn how to apply these state-of-the-art therapies to enhance patient outcomes.
Comprehensive training: The two-day hands-on training program, led by Dr. Hassan Bennani, is expected to offer physicians detailed instruction on various aspects of cell therapies, from collecting tissue samples and using laboratory equipment to processing and isolating cellular products.
Adherence to regulatory and clinical guidelines: The program emphasizes the importance of implementing regulatory and clinical guidelines in a certified facility and is expected to ensure that physicians can deliver safe, effective, and compliant treatments to their patients.
Customized clinical protocols: The ISSCA Certification Program covers case protocols for various indications and is expected to enable physicians to develop personalized treatment plans tailored to their patients’ specific needs.
Enhanced professional credibility: By obtaining certification from the reputable International Society for Stem Cell Application, physicians may bolster their professional credibility and showcase their commitment to providing the highest standard of care in the field of regenerative medicine.
Increased practice growth opportunities: Physicians equipped with the skills and knowledge gained through the ISSCA Certification Program are expected to be better positioned to incorporate these advanced therapies into their practice, potentially attracting more clients seeking innovative solutions.
Networking and collaboration: The program provides a platform for physicians to connect with like-minded professionals in the field of regenerative medicine, and is expected to facilitate the exchange of ideas, knowledge, and experiences.
Continuing education and support: As part of the ISSCA community, certified physicians will have access to ongoing educational resources, research updates, and support to help them stay at the forefront of regenerative medicine advancements.
The ISSCA Certification Program in NK and CAR-T Cells is expected to empower physicians with the tools, knowledge, and resources necessary to integrate these innovative therapies into their practice, elevating patient care and enhancing professional growth.
Target Audience and Relevance
This innovative certification program is aimed at doctors seeking training, products, and equipment in regenerative medicine, regardless of their prior experience. It is particularly relevant for doctors interested in staying up-to-date with the latest technologies and protocols, those caring for patients with conditions treatable with cell therapies, and aesthetic doctors. The program caters to doctors with interests in new research on stem cells, MSCs, exosomes, regenerative medicine and medical networks.
ISSCA at Global Perspective
ISSCA has been at the forefront of promoting excellent and standardized regenerative medicine. For more information and updates. visit us at https://www.issca.us/
The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of Regenerative Medicine to treat disease and lessen human suffering. Its members are leaders in setting standards and promoting excellence in regenerative medicine, related education, certification, research and publications.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
The International Society for Stem Cell Applications (ISSCA) Launches Comprehensive Specializations in Regenerative Medicine
Miami, Florida – The International Society for Stem Cell Applications (ISSCA) is proud to announce the launch of its new Specializations in Regenerative Medicine and Cell Therapies. These programs are specifically designed to equip medical professionals with the latest knowledge and skills they need to provide cutting-edge treatments to their patients using cellular therapies in their respective areas of expertise.
Stay Ahead of the Curve
Medical professionals seeking to stay ahead of the curve in regenerative medicine and cell therapies can now take advantage of the International Society for Stem Cell Applications (ISSCA) new Specializations in Regenerative Medicine and Cell Therapies. These comprehensive programs are designed to equip professionals with the latest knowledge and skills in the field, enabling them to offer cutting-edge treatments to their patients.
By participating in these specialized programs, medical professionals will gain access to cutting-edge research, technology advancements, and clinical protocols, ensuring that they are well-prepared to meet the ever-evolving demands of the regenerative medicine industry. In addition, ISSCA’s Specializations in Regenerative Medicine and Cell Therapies provide practitioners with an opportunity to enhance their clinical practice and improve patient outcomes through the implementation of advanced, evidence-based therapies.
Specializations Taught by ISSCA
The specializations, taught by world-class physicians and experts in different areas of specialization in Cellular Therapies and Regenerative Medicine, offer a comprehensive and rigorous program that will prepare students for success in their respective fields. The courses include a variety of topics such as harvesting and processing of adipose- and bone marrow-derived stem cells, regenerative gynecology, hair regeneration, immune system optimization, cellular therapies in dermatology, tissue engineering, allogeneic cell therapy, ozone therapy, prolotherapy, functional regenerative medicine, pain management, and chemical blepharoplasty.
“We are thrilled to offer these new specializations to medical professionals globally,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application from the USA. “Our goal is to provide the best education and training in regenerative medicine and cell therapies so that professionals can provide the highest quality care to their patients.”
ISSCA’s Specializations program includes renowned physicians and experts from around the world. Dra. Silvina Pastrana (Argentina) will provide certification in harvesting, processing, and clinical application of adipose-derived stem cells and bone marrow-derived stem cells, as well as ozone therapy and prolotherapy. Dr. Jorge Elias (Argentina) will teach regenerative gynecology and bioidentical hormones, while Dr. Melihcan Sezgic (Turkey) will cover hair regeneration and transplantation.
Other instructors include Dr. Hassan Bennani (USA) and Dr. Antonio Carrasco (Peru) for immune system optimization, Car-T and NK cells, Dra. Andrea Lapeire (Argentina) for cellular therapies in dermatology and aesthetic medicine, Dr. Alan Gaveck (USA) for allogeneic cell therapy, Dr. Mario Ojeda (Chile) for functional regenerative medicine and obesity, Dr. Ramón Saldaña (Dominican Republic) for pain management, orthopedics, and traumatology, and Dr. Saverio Di Blasi (Venezuela) for chemical blepharoplasty and facial rejuvenation techniques.
ISSCA’s Specializations program is a unique opportunity for medical professionals to gain knowledge and expertise from world-renowned experts in regenerative medicine and cell therapies. With this comprehensive and rigorous curriculum, students can develop the skills and knowledge necessary to provide the highest quality care to their patients.
For more information and to register, visit the ISSCA website.
Platform for Industries Leaders
The ISSCA Conference on Regenerative and Cellular Therapies also serves as a platform for industry leaders, researchers, and practitioners to exchange ideas, discuss new findings, and collaborate on groundbreaking projects in the field of regenerative medicine. This interaction fosters innovation and growth, enabling attendees to stay ahead of the curve and contribute to the advancement of the industry.
As the field of regenerative medicine continues to evolve and expand, it is crucial for medical professionals to remain current on the latest developments and best practices. ISSCA’s Specializations in Regenerative Medicine and Cell Therapies provide a comprehensive education and training platform for professionals to acquire the necessary knowledge and skills to excel in this exciting and rapidly growing field.
Invest in Education
By investing in their education and staying ahead of the curve, medical professionals can ensure that they are at the forefront of regenerative medicine, delivering the highest quality care and most effective treatments to their patients. Through ISSCA’s specialized programs and conferences, practitioners will be well equipped to navigate the dynamic landscape of regenerative medicine and cell therapies, positioning themselves as leaders in this innovative field.
ISSCA at Global Perspective
ISSCA has been at the forefront of promoting excellent and standardized regenerative medicine. For more information and updates. visit us at https://www.issca.us/
The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of Regenerative Medicine to treat disease and lessen human suffering. Its members are leaders in setting standards and promoting excellence in regenerative medicine, related education, certification, research and publications.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
ISSCA Announces Upcoming Conference on Regenerative Medicine and Cellular Therapies in Buenos Aires
The International Society for Stem Cell Application (ISSCA) – a Global Stem Cells Group (GSCG) division – is thrilled to announce its upcoming Conference on Regenerative Medicine and Cellular Therapies in Buenos Aires, Argentina.
The conference is scheduled at the Marriott Hotel on June 3-4, 2023. This spectacular event offers scientists and medical professionals an excellent opportunity to broaden their knowledge of regenerative medicine. Attendees will learn about the latest clinical applications of stem cell therapies from elite speakers, including scientists and physicians with extensive experience in the field.
Highlights of the Conference
Hear from Professionals
The event offers an all-inclusive program featuring hands-on certification, workshops, and theoretical lectures. Attendees will have the opportunity to communicate with like-minded experts from all walks of life and become part of an evolving community leading the future of medicine.
An Opportunity to Network
Medical practitioners and stakeholders can learn from experts in the industry through this leading international program. All stakeholders and practitioners are welcome to attend the event. These include:
● Doctors, Researchers & Innovators.
● Decision-makers and funding agencies.
● Experts seeking collaborative work on stem cell technology.
● Professional bodies.
● Marketing professionals.
Hands-On and One-On-One Training by Experienced Instructors
The conference will feature hands-on and one-on-one training sessions with professional, ISSCA-certified instructors. Attendees will get intensive hands-on experience with stem cell therapy’s aesthetic and clinical application. The event will last for two days, with one day set apart for lectures and two days for hands-on certification from professionals in the field. ISSCA will give attendees a certificate of completion upon program completion.
Knowledge of a Wide Range of Topics in Stem Cell Research
A panel of esteemed experts on stem cells and regenerative medicine will feature at the conference. They will conduct a one-day rigorous research-based discussion on the vital topic covering stem cells and regenerative medicine.
The conference will focus on a wide range of topics, including:
● Updates in stem cell research.
● Clinical applications of cellular therapies and regenerative medicine.
● The modern methods of harvest and isolation.
● Non-invasive surgical guidelines.
● Regenerative medicine and tissue engineering.
● Techniques for the effective delivery of cell products.
● Regulatory and ethical challenges in stem cell technology.
● Modern technologies to enhance marketing and networking.
The attendees of the conference will be treated to a gala dinner that includes a gourmet wine tasting at the Marriot Hotel at the conclusion of the first day’s proceedings. On June 4, the second day of the event, Dr. Silvina Pastrana and Dr. Andrea Lapeire, both certified ISSCA mentors hailing from Argentina, will be conducting an extensive hands-on training session on the clinical and aesthetic applications of stem cell therapy.
For science and medical professionals seeking to advance their skills and knowledge in regenerative medicine, the ISSCA Conference on Regenerative Medicine and Cellular Therapies is a must-attend event. Attendees will acquire knowledge and access to diverse brands, products, and technologies for stem cell therapy.
For attendees, one of the main advantages of attending the conference is the opportunity to learn about the following:
● Latest technologies.
● Products and equipment for stem cell therapy.
● Tissue engineering.
● Regenerative medicine in general.
ISSCA is delighted to announce an impressive lineup of renowned speakers for its upcoming event, including:
● Dr. Salih Yildirim, ISSCA Overseas Director from Turkey
● Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application from the USA
● Dr. Silvina Pastrana and Dr. Andrea Lapeire from Argentina
● Dr. Melihcan Sezgic from Turkey
● Dr. Julian Petrolito, Prof. Dr. Julio Ferreira, Dr. Pedro Celeri, Dr. Florencia Leinado, Dr. Hernan Diego Iriarte, Dr. Alejandro Guala, Dr. Afonso Ciancagili, and Dr. Jorge Elias, all from Argentina
● Dr. Roni Moya from Portugal
● Dr. Ramon Antonio Saldaña from Dominican Republic
To learn more about the ISSCA Buenos Aires, Argentina conference and to make a reservation, visit the https://www.issca.us/issca-world-conferences/ website, email info@stemcellsgroup.com, or call +1305 560 5337.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and regenerative medicine.
ISSCA updates its members on advances in stem cell research, MSC, exosomes, and regenerative medicine
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
The international community provides a platform for practitioners to interact with scientists and build medical networks necessary for marketing.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities worldwide. The goal is to encourage more physicians to practice regenerative medicine and make it available to patients nationally and internationally. Incorporated under the Republic of Korea as a non-profit company, the ISSCA is focused on fostering excellence and standards in regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
International Society for Stem Cell Application (ISSCA) and Marmara University Launch Stem Cell and Regenerative Medicine Fellowship Program in Turkey
Participants in the program will have access to over 200 hours of valuable online content and hands-on laboratory practice in the state-of-the-art facilities at Marmara University and StemBio. Generally, the program will cover a series of topics related to the general principles of regenerative medicine, including:
- Stem cell biology;
- Evidence-based treatments; and
- Tissue engineering.
Hear from Certified and Established Industry Leaders
The Stem Cell and Regenerative Medicine Fellowship Program aims to provide attendees with the chance to meet, interact, and learn from ISSCA-certified doctors, scientists, experts, and Marmara University professors with in-depth expertise in the field. There will be seven days of in-person training and a comprehensive digital course offering practical experience in stem cell classifications and laboratory applications, with a high emphasis on Good Manufacturing Practice (GMP) guidelines.
Learn About the Best Stem-Cell Application Practices and Procedures in Clinical and Manufacturing Operations
By attending the program, participants should be able to gain valuable answers to the “how to” questions related to the practical applications of stem cell biology and regenerative medicine in research laboratories and manufacturing facilities. Attendees can expect to learn the following:
- How to culture stem cells;
- How to meet quality control standards;
- How to comply with cGMP functions;
- How to operate within the recommended clinical procedures;
- How to apply and implement the regulations for stem cell processing in a certified manufacturing facility; and
- How to apply clinical guidelines and regulatory policies when developing a GMP facility
Besides, the seven-day fellowship program will also offer participants resources to bolster their stem cell operations, including copies of presentations, procedural guidelines, and all forms and documentation related to a GMP facility.
Moreover, the Stem Cell and Regenerative Medicine Fellowship Program will cover a range of clinical procedures, including:
- Tissue processing;
- Isolation of mesenchymal stem cells;
- Culture, Expansion and cryopreservation; and
- Clinical Application of stem cells for wide-ranging indications: participants will get case books and complete protocols for about 30 indications.
Why Attend the Stem Cell and Regenerative Medicine Fellowship Program?
The program provides a learning experience for medical professionals and scientists who’d love to further their knowledge and skills in stem cells and regenerative medicine. Attendees will get the opportunity to learn from the top professionals in the field and gain practical hands-on experience in world-class laboratory facilities.
Here’s what Global Stem Cells Global’s CEO, Benito Novas, had to say: “We are delighted to hold the Stem Cells and Regenerative Medicine Fellowship Program, which is designed to provide participants with the opportunity to gain and further their knowledge in stem cell biology and tissue engineering. In addition, ISSCA’s partnership with Marmara University will ensure attendees have access to professors with deep knowledge in the field and practical training in stem cell and regenerative medicine.”
For more information on the Stem Cell and Regenerative Fellowship Program, visit the ISSCA website or contact Global Stem Cells Group.
About Marmara University
Marmara University is a leading research university nestled in Istanbul, Turkey. It’s a distinguished academic institution with high authority in scientific research and academic excellence, specifically in medicine. The university provides undergraduate, graduate, and doctorate degrees, as well as certificate programs. Marmara University also boasts state-of-the-art facilities and dedicated faculty that chronicle its dedication to giving scholars world-class learning experiences and contributing to the advancement of knowledge in wide-ranging fields.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
ISSCA is Pleased to Announce the Launch of its Comprehensive Online Course in Regenerative and Functional Medicine for Obesity Management
The International Society for Stem Cell Application (ISSCA) is proud to announce the launch of its latest online course, “Curso en Medicina Funcional Regenerativa y Obesidad / Course in Functional Regenerative Medicine and Obesity.” This comprehensive course is designed to provide students with a deep understanding of various aspects of obesity treatment, metabolic syndrome, and post-procedure management of patients.
“This course should provide students with the knowledge and skills necessary to succeed in the field of regenerative and functional medicine,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application from the USA. “We are committed to providing students with a comprehensive understanding of the latest advancements in the field and how to effectively care for patients”.
The course covers various key concepts of regenerative and functional medicine for obesity management, and gastric balloon, a safe and effective non-surgical treatment, as one of them. The course will feature in-depth insights into the fundamentals of this procedure and how they can be used to help patients achieve and enjoy healthy weight loss. Additionally, post-procedure management approaches and protocols, will be covered.
Apart from balloon therapy, the course will also explore a wide range of other related topics, such as vitamins, exosomes, trace elements, minerals, hydrolyzed collagen, and more, and their significance in obesity management. These topics should prove useful to practitioners and course other course attendees in understanding metabolic syndrome and the best post-procedure practices for managing patients.
The course will be taught by two highly experienced and well respected professionals in the field of medicine:
Dr. Mario Ojeda, Director and Member of the Chilean Society of Aesthetic Medicine and Surgery (SOCHIMCE). An international reference and renowned expert in various areas, including obesity, intragastric balloons, endoscopic gastroplasty, stem cells, gastroenterology, digestive endoscopy, and colonoscopy, Dr. Mario Ojeda is “pleased to be part of this comprehensive online course and to provide students with the necessary knowledge and skills to advance the field of regenerative and functional medicine.”
Dr. Silvina Pastrana, Head of the ISSCA chapter in Latin America. She is a specialist in general surgery and has extensive experience in aesthetic and anti-aging medicine, orthomolecular medicine and nutrition, cellular therapies, and more. As a trainer in cellular therapies, she is well-equipped to provide students with a comprehensive understanding of the latest advancements in the field.
ISSCA is committed to advancing knowledge in regenerative and functional medicine for better obesity management. This comprehensive online course should provide physicians and specialists with a complete understanding of the latest advancements in the field and how to effectively manage patients, post-procedure.
For more information about the course and how to enroll, please visit the ISSCA visit the ISSCA website, send an email to info@stemcellsgroup.com, or call +1305 560 5337
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advancements in regenerative medicine. It is the educational division of the Global Stem Cells Group focused on promoting excellence and standards in the field of regenerative and functional medicine.
Through training and advancement courses, ISSCA aims to encourage physicians and specialists to practice new and advanced regenerative medicine approaches to benefit patients globally. It also ensures that practitioners learn, meet, and adhere to the necessary regenerative medicine standards and certifications.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
Global Stem Cells Group announces participation in IV Jornadas de Actualización Medestética 2023
Global Stem Cells Group (GSCG), a leading provider of regenerative medicine solutions, is proud to announce its participation in the IV Jornadas de Actualización Medestética 2023 through the International Society for Stem Cell Association (ISSCA), its educational division and also with its line of Cellgenic Exosomes products.
The congress, which will take place on March 30th and 31st at Paseo La Plaza in Buenos Aires, Argentina, will provide a platform for ISSCA to share its knowledge and expertise in regenerative medicine with the Argentine medical community.
ISSCA is a multidisciplinary community of physicians and scientists whose mission is to advance the science, technology, and practice of regenerative medicine to treat disease and lessen human suffering. The organization has been at the forefront of promoting excellent and standardized regenerative medicine and will continue to participate in similar medical events such as this one.
The Global Stem Cells Group will also have a booth at the event to showcase its products, Cellgenic Exosomes, in its two presentations: “Cellgenic Lyophilized Exosomes” and “Cellgenic Flow Exosomes.” Additionally, it will provide guidance on how to use the products on patients.
As part of the program, ISSCA faculty members will be giving presentations and holding practical workshops to demonstrate the latest applications of regenerative medicine. The ISSCA program will cover all aspects of regenerative medicine including guidelines and clinical protocols.
“We are excited to take part in this congress and share our expertise, knowledge, and cellgenic exosome product line with the Argentine medical community,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application from the USA.
The IV Jornadas de Actualización Medestética 2023 will feature various ISSCA-certified doctors and experts as speakers, including:
Dr. Silvina Pastrana
Dr. Pastrana heads the ISSCA chapter in Argentina and serves as the medical center’s director. “Traditional, advanced, and cutting-edge anti-aging and rejuvenation medicine” will be her theme at this congress. Dr. Silvina will deliver a 40-minute summary of all the regenerative medicine and cell therapies that are now being used to postpone aging and enhance quality of life. therapies using NK cells, fluid and lyophilized exosomes, allogenic therapies, and autologous cells.
Dr. Andrea Lapeire
Dr. Lapeire is a doctor of aesthetic medicine with advanced degrees in environment, homotoxicology, biological medicine, and obesity. She will speak on alopecias: traditional and cutting-edge. Exosome Use and Biological Stimulation Fundamentals.
Prof. Dr. Julio Ferreira
Professor Ferreira is from Argentina and is a professional cosmetic surgery and aesthetic medicine expert. He is a university professor of medicine and is the president of the South American Academy of Aesthetic Surgery. He will cover regenerative therapies in rejuvenation and facial harmonization in his lecture.
Dr. Alfonso Ciancaglini
A specialist in Medical Clinic and regenerative medicine, Dr. Alfonsoi is a member of the International Society For Cellular Therapy Application and holds a certification from the Stem Cells Group. His presentation will discuss the use of regenerative medicine to treat venous ulcers.
Benito Novas
Benito Novas is the Head of Public Relations for the International Society for Stem Cell Application from the USA. He is the senior marketing consultant and founder of “Estética marketing INC” as an Author, he has authored several books among them: Su clinica este’tica. Lo que dicen sus pacientes” Marketing Digital en su Clinica Estetica” and “Marketing en Tiempos de Crisis” for more information on Novas you can check on www.benitonovas.com. In this congress. Benito Novas will be covering Digital Marketing in Cash-based practices.
ISSCA at Global Perspective.
ISSCA has been at the forefront of promoting excellent and standardized regenerative medicine. For more information and updates. visit us at https://www.issca.us/
The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of Regenerative Medicine to treat disease and lessen human suffering. Its members are leaders in setting standards and promoting excellence in regenerative medicine, related education, certification, research and publications.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
Global Stem Cells Group (GSCG) and International Society for Stem Cell Application (ISSCA) to Participate in Dubai Stem Cell Congress 2023
MIAMI, Florida, February 15, 2023 – Global Stem Cells Group (GSCG) and its educational division, the International Society for Stem Cell Application (ISSCA), are proud to announce their participation as sponsors and co-organizers of the Dubai Stem Cell Congress 2023. The congress, endorsed by the Hortman Stem Cell Laboratory, will take place on the 27th and 28th of February 2023 at the prestigious Waldorf Astoria on The Palm in Dubai.
The congress will bring together international experts in regenerative medicine and stem cell research from around the world to share their knowledge, experiences, and insights with the academic community and the general public. The event will also provide a platform for patients to share their success stories of stem cell therapy and how it has helped them overcome various life-threatening diseases.
“We are honored to welcome you to the first edition of the Dubai Stem Cell Congress 2023, which will host international experts in the field of Regenerative Medicine & Stem Cell Research from around the world,” said Dr. Fatma Alhashimi, Chairman of Dubai Stem Cell Congress. “We will be showcasing cutting-edge data, stem cell technologies, and advanced applications.”
GSCG will showcase its range of cellular products and equipment, including exosomes for topical and intravenous use, Mesenchymal Stem Cells (MSC), Bone Marrow Kit, PRP Kit, Fat Kit for obtaining Stromal Vascular Fraction (SVF), workstation, and laboratory equipment. ISSCA, on the other hand, will be represented with its training, congresses, conferences, and the fellowship in Cellular Therapies.
“Our mission is to make cellular therapies a reality for both doctors and patients, and we are happy to continue that mission by sharing our knowledge and showcasing our Cellgenic branded Cellular products and equipment at the congress,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for ISSCA.
With over 25 world-class international speakers, including ISSCA-certified speakers, the congress will feature a variety of panel discussions, lectures, and presentations on the latest innovative technologies in stem cell and regenerative medicine.
ISSCA-certified speakers and experts who will be presenting lectures at the congress include the following:
- Erdinç Civelek, a brain surgeon at Gaziosmanpaşa Taksim Hospital for Research and Education in Turkey.
- Dr. Serdar Kabataş, a brain surgeon at Gaziosmanpaşa Taksim Research and Education Hospital in Turkey.
- Abdulmajeed Hamadi, a consultant hematologist and pioneer in transplantation and stem cell therapy with an FRCP designation in Iraq.
- Salih Yildirim, the Director of Overseas Operations of ISSCA and a member of the Board of Directors of the Global Stem Cell Group and Director of International Operations.
- Benito Novas, the Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for the Application of Stem Cells in the USA.
Among the esteemed speakers at the event are:
Prof. Anil Dhawan, Dr. Frances Verter, Dr. Masayo Takahashi, Dr. Essam Abdelalim, Prof. Shuibing Chen, Prof. John E. Wagner, Mrs. Kim Petrella, Dr. Edward Guindi, Dr. Mazaiah Yaacob, Dr. Mohammed Moulay, Mr. Oliver Papavlassopoulos, Dr. Sean Ng, Dr. Chiara Cugno, Dr. Siti Aminah, Mr. Thomas Moss, Prof. Dr. Tim Schulz, Dr. Luis Saraiva, Mrs. Renata Mihályová, Dr. Srinivasan Periathiruvadi and Dr. Ahmed Foul.
For the first time in the UAE, patients will have the opportunity to share their success stories of stem cell therapy, including the story of Mahra, a UAE national and survivor of Thalassemia, and the world’s first cord blood patient, Matthew Farrow.
Stem cell therapy is the present and future of medicine and holds the “Hope That Brings Life” to many patients in need. The Dubai Stem Cell Congress 2023 is a landmark event that will bring together leading experts, patients, and members of the academic community to share their experiences and knowledge about stem cell therapy and its advancements.
To learn more about the Dubai Stem Cell Congress 2023 and to make a reservation, visit the https://dubaistemcellcongress.com/ website, email info@stemcellsgroup.com, or call +1 305 560 5337.
About Hortman Stem Cell Laboratory
Mr. Darius Curta Managing Director of Hortman Healthcare Investment – Hortman Stem Cell Laboratory is the first state-of-the-art laboratory within the field of Stem Cells and Regenerative Medicine, focused on providing top-notch cord blood banking solutions. Additionally, our institution will be facilitating the first ever clinical trials in stem cell research in UAE. Hortman Stem Cell Laboratory, located at Golden Mile, Palm Jumeirah, consists of GMP Laboratories & ISO Clean Rooms for stem cell isolation, culture & expansion. Such a facility enables us to provide a solid foundation for successfully establishing an awareness and understanding of stem cells within the Middle Eastern Region. Hortman is leading that charge at the forefront of the research community.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
ISSCA’s On-site Training in Portugal
MIAMI, Florida, January 23, 2023 – The Global Stem Cells Group (GSCG) announces its long-awaited hands-on training this March 9th, 10th & 11th, 2023
The GSCG, through its International Society for Stem Cell Application (ISSCA) division, is holding a personalized, hands-on training course at Regenera clinic, located in Oeiras, Lisboa, Portugal. Industry-leading instructors across the regenerative medicine field will lead this onsite training course. We believe this course is a Total Solution for clinics as ISSCA teams will teach and train doctors and caregivers on the recent advances in regenerative medicine and cellular-based treatments.
Lisboa’s First On-site Training
Benito Novas, CEO of Global Stem Cells Group and Vice President of ISSCA, notes that “regenerative medicine is the future of health and beauty industries as more research is conducted and products developed for doctors to offer a superior service.”
Benito adds, “the training course will take a highly visual format with global experts interacting with trainees and live patients used to teach about different stem cell reintegration and procedural techniques with locally available tools and facilities.
The Lisboa training is the first in the country to bring clinics into the fold of regenerative medicine and stem cell treatments. Regenera clinic will be the first to be ISSCA certified and apply cellular therapies and regenerative medicine. Dr. Roni Lara Moya will be appointed Portugal Chapter director on 9th March.
The course design considers the needs of local trainees using a thorough scheduling process. Initial consultations between the trainees and ISSCA will inform equipment and kits availability, materials, underlying costs, and any other needs to be met during the main event.
What is the On-site Training About?
The following are some of the areas the onsite-training course will focus on:
1. Learning from Experts
A panel of stem cell therapy and regenerative medicine experts will lead the one-on-one training sessions. Cell therapy, skin regeneration techniques, bone marrow extraction, tissue engineering, and many more applications of advanced technologies to advance personalized health will be practically illustrated.
2. Trainees-Centered Treatment Protocols
The training course is personalized to every doctor and clinician’s specialization and the illness they are targeting. For example, stem cell treatment sessions will include various reintegration methods based on patients’ medical history and condition. The trainees will also have a first-hand view of how technology pushes the boundaries of regenerative medicine from research to the derivation of cell lines and, as we are all working to the possible future of genetic alteration.
Local nurses and medical assistants will also have a chance to be part of the process by going through a fully skilled procedural session that improves their assistance to the doctors.
3. International Certification
As an acclaimed stakeholder in regenerative medicine and stem cell treatment, ISSCA offers globally recognized certification to doctors and practitioners, highlighting their fascinating journey in this highly demanded field. According to the appointed chapter director of Portugal, Dr. Roni Lara Moya- “the upcoming onsite training is one of its kind ever conducted in the country. Dr. Moya asserts that “the collaboration between ISSCA and Regenerative Biomedicine Regenerative Clinic stems from a growing demand for new technologies and cutting-edge treatments that support patients’ positive health outcomes.”
4. Trends in Regenerative & Stem Cell Treatment
The training will cover stem cell and regenerative medicine’s practical, legal, technical, and ethical aspects. Laws, technological developments, and ethical concerns will be a critical part of the training course.
All are welcome to share the fantastic excitement of stem cell science and its promising future.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
Mesenchymal Stem Cells For Cardiovascular Diseases
Despite progress in cardiovascular research, cardiac pathology continues to be one of the most common causes of morbidity and mortality in the world. Stem cell-based therapy has been recognized as an innovative strategy for the repair, regeneration and functional recovery of the myocardium, hence, once the animal research stage has been overcome, most clinical trials aimed at evaluating the safety and effectiveness of regenerative medicine in cardiovascular diseases have focused on angina pectoris, myocardial infarction and chronic cardiomyopathy. Although the current evidence of benefit is not conclusive, the evidence in favor of favorable results is growing.
In some cases, stem cell therapy can provide an effective treatment or alternative for diseases or disorders for which there is no effective treatment. Because these cells are capable of dividing into a wide range of lineages and tissues, they can be used to treat various diseases by repairing, replacing, and regenerating tissues.
It is unclear how umbilical cord mesenchymal stem cells act on the heart, but previous studies have shown that they possess an anti-apoptotic effect. The induced cardiomyocytes can form discs interspersed with myocytes from the host cells, creating a functional syncytium that will help contract the heart. Mesenchymal stem cells can improve cardiac function and reduce damage caused by cardiovascular disease, since they stimulate endogenous repair mechanisms, the regulation of the immune response, tissue perfusion and the proliferation of the resident heart rate, thereby improving cardiac function and reducing damage severity.
Refractory angina
This syndrome, characterized by persistent angina despite standard medical treatment, is often not revascularized due to diffuse coronary lesions or severe comorbidities.
In 2017, a review included 13 clinical studies, with 1061 patients and 12 months of follow-up on average, indicating cell therapy has emerged as a tool for managing these patients. Although the available data are inconclusive, the authors conclude that stem cell-based therapy could be a viable addition to conventional treatment options for refractory angina, given the paucity of therapeutic alternatives.
There was a reduction in mortality at two years after a meta-analysis in 2018, involving 304 patients, showed improved exercise tolerance and reduced angina attack frequency at three, six and 12 months. An additional meta-analysis published in March 2019, involving 526 patients monitored for 14 months, showed that patients treated with stem cells had fewer serious adverse effects, fewer deaths, fewer angina attacks, and fewer antianginal medications than those treated with conventional management.
A third meta-analysis from 2019, with 269 patients and 15 months of follow-up on average, reports the following results: decreased all-cause mortality, decreased frequency of angina and increased exercise time, with no increase in adverse reactions.
Cardiomyopathy (ischemic and non-ischemic)
Despite optimal medical and surgical management, many patients with heart failure undergo long-term myocardial remodeling that does not allow them to restore their ventricular function. This is because current treatment protocols cannot reverse the loss of cardiomyocytes due to cardiomyopathy. Since inflammatory responses continue over time as a central mechanism in the development of heart failure, it was of interest to investigate the anti-inflammatory, antifibrotic, and immunomodulatory properties of stem cells in patients with ischemic and non-ischemic cardiomyopathy.
In a review of five clinical studies published between 2017 and 2018, including 605 patients, the authors conclude that cell therapy is safe, causes immunomodulatory effects, improves functional capacity, and adds clinical benefits to standard therapies. According to them, the results are promising, and further evidence strengthening is recommended.
Based on a meta-analysis published in May 2019, involving 20 investigations and 1418 patients evaluated for an average of 21 months, stem cells improved cardiac function indicators (LVEF and LVESV), walking distance, functional classification of heart failure, quality of life, and mortality as compared to controls. Hospitalizations and serious adverse events were not different from those in the control group.
In a recent review of 9 studies involving 612 patients with heart failure, improvement was found in clinical and paraclinical parameters, evaluated on average for 9 months. According to the authors, stem cells are an effective therapy for the treatment of heart failure, improving patient prognosis and ability to exercise.
Acute myocardial infarction (AMI)
The application of stem cells was associated with a significant increase in left ventricular ejection fraction (LVEF) and other variables indicative of improved ventricular function and modification of remodeling in patients with AMI receiving timely percutaneous coronary intervention (PCI) and conventional medication in different studies. Even coronary artery bypass grafting with stem cells offers greater benefits. A number of studies have also shown that intravenous administration could be a more efficient and effective method of treating the heart or coronary arteries than direct application, with logistic, safety, and cost advantages.
Stem cell therapy is evidenced to be a safe way to treat cardiovascular diseases, as it shows an anti-apoptotic effect, reduction of lesion size, improvement of cardiac function through regulation of the immune response, adequate tissue perfusion and activation of growth factors.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Blog
Atherosclerosis obliterans grade IV: Application of Autologous Stem Cells
Atherosclerosis is the most common form of arterial occlusive disease in adults. About 15 percent of adults over 55 years of age suffer from critical ischemia, the most severe form of this disease.
Due to the gradual aging of the population and the growing number of people in their third age group, a number of studies have been conducted in order to improve the prognosis of atherosclerosis obliterans and to find alternatives to the mutilation of the extremities. As a general rule, chronic ischemia of the lower limbs should be treated to alleviate symptoms, particularly pain, prevent disease progression, and reduce the rate of amputations. In most patients with critical ischemia, the main goal is to preserve the affected limb.
The development of regenerative medicine is closely linked to the development of new knowledge about embryonic and adult stem cells, as well as the regenerative and therapeutic potential of stem cell therapy. The use of adult stem cells in the treatment of peripheral artery diseases has been demonstrated as a therapeutic agent for inducing angiogenesis. Recent preclinical studies as well as the pioneering clinical studies indicate that bone marrow-derived mononuclear cells (MBMCs) can enhance tissue vascularization in ischemic limbs, with results similar to those obtained with peripheral blood stem cells supply.
Cuba presented the first studies carried out in 2004 at the Institute of Hematology of the “Enrique Cabrera” hospital in Havana City, which achieved encouraging clinical results and had very few adverse effects in recent years.
A progressive rise in the accumulated experience with stem cells was also observed in Pinar del Rio in 2005, as the first 10 cases were carried out. The rising ease of obtaining this type of cell has made research and applications with these cells advance rapidly with great expectations in terms of clinical application.
A study published by Dia-Diaz, et al. in the Journal of Medical Sciences of Pinar del Rio examined 296 patients with grade IV atherosclerosis obliterans between 2009 and 2019. During the study, autologous stem cells were injected intramuscularly from peripheral blood. Within four weeks, pain relief was observed, as well as an increase in the pain-free claudication distance. Angiography after treatment revealed collateral vessel formation. The limb was saved in 201 patients (68%), while 95 cases (32%) presented amputation criteria. Complications were not reported following the procedure.
The study demonstrated the effectiveness of the implantation of autologous stem cells obtained from peripheral blood, as well as the favorable evolution of patients, clinical improvement of rest pain, walking distance without claudication and ankle-brachial pressure index.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Blog